Key Highlights

● MRNA shares rose 6.95% to $203.21 on Monday, October 5, on 19.31 million shares, about 1.16 times normal volume.

● The Phase 3 INTerpath-001 melanoma trial of intismeran autogene, developed with Merck, met its primary endpoint of recurrence-free survival, with detailed data scheduled for the ESMO congress in Madrid.

● Moderna rejoins the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery.

● Second-quarter Revenue was $145 million and the net loss was about $0.8 billion, with $6.9 billion in cash and investments at the end of June.

Two countdowns drove Moderna (NASDAQ:MRNA) higher on Monday: the full public presentation of its personalized cancer Vaccine data later this month, and the stock's return to the Nasdaq-100 index on Friday. Shares rose 6.95% to $203.21 on 19.31 million shares, about 1.16 times normal volume, for roughly $3.92 billion in dollar volume, 19th among US stocks. The gain extended an extraordinary run: Moderna had risen 594% this year through Friday's close.

What's driving the volume

The biggest driver is anticipation around intismeran autogene, the individualized mRNA cancer therapy Moderna is developing with Merck (NYSE:MRK). In August the companies said the Phase 3 INTerpath-001 trial in high-risk melanoma, which enrolled 1,137 patients after surgery, met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival when intismeran was added to Merck's Keytruda. The detailed numbers have not yet been released. They are scheduled for a Presidential Symposium at the European Society for Medical Oncology congress in Madrid, reportedly on October 24. The rally has been built on results almost no one outside the trial has seen in full.

Index mechanics add a second layer. On October 1, Nasdaq announced that Moderna will rejoin the Nasdaq-100 before the market opens on October 9, replacing Warner Bros. Discovery (NASDAQ:WBD). Moderna was dropped from the index in December 2024, when its shares had collapsed. Funds that track the Nasdaq-100, which Nasdaq says are linked to more than $800 billion in assets, must buy shares around the effective date, and traders often position ahead of that demand. For now, Moderna's benchmark memberships are the S&P 500 and the Russell 1000; the Nasdaq-100 listing takes effect only on Friday.

Monday was also a busy day for vaccine stocks in general. Novavax (NASDAQ:NVAX) soared 22% after news that Sanofi is distributing its Nuvaxovid COVID shot in several countries for the fall season. But Moderna's gain came from its own cancer pipeline rather than respiratory vaccine news; BioNTech (NASDAQ:BNTX) barely moved, Pfizer (NYSE:PFE) slipped and the iShares Biotechnology ETF rose only about 1%.

The scale of the move helps explain the volume. The shares had climbed about 202% between mid-August, when the trial's top-line success was announced, and the end of last week. A stock that has moved that far that fast attracts momentum traders, short sellers and Options activity, and each new headline produces outsized swings. Monday's relative Volume of 1.16 was only modestly above average, but at a share price above $200, ordinary turnover now translates into billions of dollars a day, far more than when the stock started the year below $30, as the year-to-date gain implies.

The business

Moderna rose to prominence with its COVID-19 vaccine, Spikevax, built on messenger RNA technology that instructs cells to make a target protein. As Pandemic sales faded, revenue shrank dramatically and the company has spent heavily to broaden its portfolio. Its pipeline now includes a seasonal flu vaccine, mFLUSIVA, a flu and COVID combination shot, mCOMBRIAX, which has received European Marketing authorization, a respiratory syncytial virus vaccine, rare-disease programs such as a therapy for propionic acidemia, and the oncology work with Merck. Not everything has worked: an interim Phase 3 analysis of its norovirus vaccine did not meet early success criteria.

Recent results and guidance

The financial picture remains that of a company in transition. For the second quarter of 2026, Moderna reported revenue of $145 million, roughly flat with a year earlier, and a net loss of about $0.8 billion, or $1.97 per share. It ended June with $6.9 billion in cash and investments, after paying a $950 million litigation settlement in July. For the full year, the company guided to revenue growth of up to 10% from 2025 and cut its Research and Development outlook by about $100 million to $2.9 billion, while lifting its year-end cash projection to between $4.7 billion and $5.2 billion. Trailing revenue is about $1.94 billion, and trailing diluted losses are $7.98 per share.

Valuation

Because Moderna is losing money, a price-to-earnings ratio is not meaningful, and comparisons rest on sales and expectations. At an $81 billion market value, the stock trades at more than 40 times trailing revenue. Using an earlier price, the price-to-sales ratio was about 33, against a historical median of roughly 8. That valuation implies investors are assigning a large value to intismeran; Peak sales estimates for the vaccine run around $5 billion. Analyst views lag the price badly. The average analyst target is about $119, far below Monday's close, and the consensus rating is Neutral. Citigroup (NYSE:C) has turned more cautious, warning that sales expectations may be too optimistic given the valuation and the still-pending data.

Bull case

Bulls see intismeran as a potential new pillar for the company and a validation of mRNA beyond infectious disease. Bank of America (NYSE:BAC)'s Alec Stranahan said the result could let Moderna diversify away from infectious disease. A positive, clearly presented dataset at ESMO could support broader use in melanoma and trials in other tumors. Lower spending, a strengthened cash forecast, new respiratory products and Nasdaq-100 inclusion all add to the case, and the momentum itself attracts buyers.

Bear case

The bear case is about binary risk and price. A top-line announcement without numbers can look very different once hazard ratios, confidence intervals and follow-up curves are public, and any disappointment at ESMO could reverse a large part of this year's gains. The core Business still loses money, the vaccine market remains difficult, and analyst targets sit far below the share price. Insiders also sold roughly $65 million of stock over the past year. Index-driven buying often fades once inclusion is complete.

The ESMO data release and Moderna's Nasdaq-100 return

The near-term calendar is unusually crowded. Moderna joins the Nasdaq-100 before the open on Friday, October 9, and the full INTerpath-001 results are due at ESMO later in October. Investors will scrutinize the size of the benefit, the durability of the curves and safety data, then turn to third-quarter results, fall respiratory vaccine sales and any updates on regulatory filings for the cancer vaccine.